Cannabis fails to demonstrate meaningful effectiveness in treating anxiety, depression or post-traumatic stress disorder, according to one of the most extensive analyses of medicinal use to date, raising fresh concerns among clinicians and regulators as consumption expands across several regions.
The large-scale review, which evaluated hundreds of clinical studies and patient data sets, found no consistent evidence that cannabis-based products alleviate core symptoms of common mental health conditions. Researchers reported that, in many cases, outcomes were indistinguishable from placebo effects, while some studies indicated a worsening of psychiatric symptoms among users.
Investigators noted that anxiety and depression, often cited as primary reasons for medicinal cannabis prescriptions, showed negligible improvement across controlled trials. For post-traumatic stress disorder, where anecdotal use has surged, the analysis found limited and inconclusive benefits, with some participants reporting heightened emotional instability or increased intrusive symptoms.
Medical experts involved in the study warned that widespread perceptions of cannabis as a therapeutic solution for mental health disorders are not supported by rigorous scientific evidence. They pointed to the growing gap between public belief and clinical findings, particularly in jurisdictions where legalisation has broadened access to both prescribed and over-the-counter cannabis products.
Concerns extend beyond inefficacy. The review highlighted elevated risks associated with regular or high-dose cannabis use, including the onset of psychosis, dependency, and cognitive impairment. Younger users and those with pre-existing mental health vulnerabilities were identified as particularly at risk. Clinicians cautioned that such outcomes could complicate treatment pathways and exacerbate underlying conditions.
Psychiatrists also emphasised that reliance on cannabis may delay patients from seeking evidence-based therapies such as cognitive behavioural therapy or clinically approved medications. “When individuals turn to cannabis as a first-line response, it can postpone interventions that have a far stronger track record,” one clinician involved in the analysis said, underscoring the risk of prolonged untreated illness.
The findings arrive amid a sharp rise in global cannabis use, driven by expanding legal frameworks and increased marketing of medicinal products. In several countries, prescriptions for cannabis-based treatments have grown significantly over the past decade, often supported by patient demand rather than robust clinical guidance. Health authorities are now facing mounting pressure to reconcile regulatory policies with emerging scientific data.
While the study’s overall conclusions were largely critical of cannabis for psychiatric conditions, researchers acknowledged limited indications of potential benefit in other areas. Some evidence suggested modest improvements in sleep disorders, particularly insomnia, although results were inconsistent and often based on small sample sizes. Similarly, early-stage findings hinted at possible applications in managing certain symptoms associated with autism spectrum conditions, though these were described as preliminary and insufficient for clinical endorsement.
Industry stakeholders have argued that variability in cannabis formulations, including differing ratios of tetrahydrocannabinol and cannabidiol, complicates research outcomes and may obscure potential therapeutic effects. However, researchers countered that such variability further undermines reliability and makes standardised treatment protocols difficult to establish.
Regulators are now being urged to tighten oversight of medicinal cannabis claims, particularly those targeting mental health conditions. Experts have called for clearer labelling, stricter advertising controls, and improved patient education to prevent misconceptions about efficacy. Some policymakers are also examining whether existing approval processes for cannabis-based products adequately reflect the level of clinical evidence required for other pharmaceuticals.
The debate is unfolding against a backdrop of shifting public attitudes, where cannabis is increasingly viewed as a benign or even beneficial substance. Public health officials warn that this perception may contribute to underestimating the risks associated with prolonged use, especially among younger populations.
